Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -2.02%129.61B | 5.75%566.44B | 4.21%156.39B | 4.44%142.51B | 10.44%135.27B | 4.46%132.28B | 2.01%535.64B | 15.61%150.08B | -11.26%136.45B | -5.86%122.48B |
Cost of revenue | -3.28%92.89B | 7.91%406.71B | 4.87%113.13B | 6.42%99.56B | 10.97%97.97B | 10.16%96.04B | 3.35%376.9B | 21.00%107.88B | -12.43%93.56B | -4.88%88.29B |
Gross profit | 1.32%36.72B | 0.63%159.74B | 2.50%43.26B | 0.12%42.94B | 9.07%37.29B | -8.14%36.24B | -1.04%158.74B | 3.79%42.21B | -8.61%42.89B | -8.31%34.19B |
Operating expense | -1.56%30.16B | -0.88%126.22B | 0.30%33.34B | -0.76%32.36B | -0.05%29.87B | -3.03%30.64B | 0.21%127.34B | -1.23%33.24B | 1.34%32.61B | -1.55%29.89B |
Operating profit | 17.06%6.55B | 6.75%33.52B | 10.68%9.92B | 2.90%10.58B | 72.40%7.42B | -28.69%5.6B | -5.81%31.4B | 27.94%8.96B | -30.32%10.28B | -37.91%4.31B |
Net non-operating interest income (expenses) | -54.09%-584M | 22.09%-991M | 288.33%339M | -36.22%-504M | -23.82%-447M | -4.99%-379M | 5.07%-1.27B | 18.92%-180M | -0.27%-370M | 2.43%-361M |
Non-operating interest income | ---- | 329.13%884M | ---- | ---- | ---- | ---- | 50.36%206M | ---- | ---- | ---- |
Non-operating interest expense | 54.09%584M | 26.86%1.88B | 41.19%545M | 36.22%504M | 23.82%447M | 4.99%379M | 0.07%1.48B | 7.52%386M | 0.27%370M | -2.43%361M |
Net investment income | 26.69%2.44B | 4.01%3.9B | -40.46%284M | 16.89%1.32B | -17.26%374M | 13.66%1.92B | 21.08%3.75B | 21.68%477M | 30.06%1.13B | 32.16%452M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 9.91%-100M | 5.25%17.21B | 1.85%16.5B | 203.35%725M | 247.76%99M | -552.94%-111M | 1,894.15%16.35B | 1,835.13%16.2B | -15.55%239M | 63.98%-67M |
Income from associates and other participating interests | 131.25%703M | -60.74%1.38B | -58.90%420M | 9.57%1.02B | -155.90%-365M | -66.41%304M | -45.07%3.51B | 171.09%1.02B | -50.85%930M | -80.27%653M |
Special income (charges) | 106.73%21M | -109.57%-971M | -102.67%-281M | -2,803.33%-871M | 278.62%493M | -333.33%-312M | 204.45%10.15B | 213.08%10.52B | 81.13%-30M | -258.44%-276M |
Less:Restructuring and mergern&acquisition | ---- | 0.00%-573M | ---- | ---- | ---- | ---- | 0.00%-573M | ---- | ---- | ---- |
Less:Other special charges | -141.18%-21M | 110.61%1.03B | 105.98%601M | 2,803.33%871M | -298.79%-493M | -29.17%51M | -200.85%-9.71B | -209.10%-10.06B | -81.13%30M | 222.08%248M |
Less:Write off | --0 | 280.74%514M | 136.45%253M | --0 | --0 | --261M | -79.58%135M | --107M | --0 | --28M |
Other non-operating income (expenses) | 28.76%685M | -57.76%362M | -31.85%-1.18B | 39.57%776M | -61.61%238M | -8.12%532M | -58.09%857M | -46.49%-898M | 15.11%556M | -62.87%620M |
Income before tax | 28.55%9.71B | -15.97%54.4B | -28.01%25.99B | 2.43%13.04B | 46.63%7.81B | -28.56%7.56B | 86.95%64.74B | 2,455.32%36.11B | -28.28%12.73B | -54.16%5.33B |
Income tax | 7.80%2.46B | -3.69%16.86B | -17.58%8.13B | 1.30%3.67B | 127.59%2.77B | -18.32%2.28B | 87.79%17.51B | 8,832.74%9.87B | -23.97%3.63B | -38.05%1.22B |
Net income | 37.53%7.25B | -20.52%37.54B | -31.93%17.86B | 2.87%9.37B | 22.66%5.04B | -32.22%5.27B | 86.64%47.24B | 1,949.12%26.24B | -29.85%9.11B | -57.45%4.11B |
Net income continuous operations | 37.53%7.25B | -20.52%37.54B | -31.94%17.86B | 2.89%9.37B | 22.63%5.04B | -32.23%5.27B | 86.64%47.24B | 1,947.82%26.24B | -29.87%9.11B | -57.44%4.11B |
Noncontrolling interests | -95.15%5M | 20.53%458M | -71.55%33M | 50.45%167M | -1.90%155M | 2,160.00%103M | -11.21%380M | -45.02%116M | -1.77%111M | 3.95%158M |
Net income attributable to the company | 40.18%7.25B | -20.86%37.08B | -31.76%17.83B | 2.29%9.2B | 23.65%4.88B | -33.60%5.17B | 88.33%46.86B | 1,702.64%26.12B | -30.10%9B | -58.42%3.95B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 40.18%7.25B | -20.86%37.08B | -31.76%17.83B | 2.29%9.2B | 23.65%4.88B | -33.60%5.17B | 88.33%46.86B | 1,702.64%26.12B | -30.10%9B | -58.42%3.95B |
Gross dividend payment | ||||||||||
Basic earnings per share | 46.78%34.1856 | -19.66%169.27 | -30.43%81.72 | 3.93%42.04 | 25.11%22.22 | -33.48%23.29 | 88.35%210.69 | 1,704.78%117.47 | -30.10%40.45 | -58.42%17.76 |
Diluted earnings per share | 46.78%34.1856 | -19.66%169.27 | -30.43%81.72 | 3.93%42.04 | 23.86%21.9983 | -33.48%23.29 | 88.35%210.69 | 1,702.80%117.4682 | -30.09%40.45 | -58.41%17.76 |
Dividend per share | 0 | 20.00%48 | 20.00%24 | 0 | 20.00%24 | 0 | 5.26%40 | 0.00%20 | 0 | 11.11%20 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |